Skip to content

Cytokines in Papillon-Lefèvre Syndrome

Observational Study on Cytokine Production by Leukocytes of Papillon-Lefèvre Syndrome Patients and Healthy Probands in Whole Blood Cultures

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01116934
Enrollment
17
Registered
2010-05-05
Start date
2006-07-31
Completion date
2009-12-31
Last updated
2016-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Papillon-Lefevre Disease

Keywords

blood culture, IL-1β, IL-6, IL-8, IP-10, interferon-gamma

Brief summary

Papillon-Lefèvre syndrome (PLS) is characterised by aggressively progressive periodontitis combined with palmo-plantar hyperkeratosis. It is caused by loss of function mutations in the cathepsin C gene. The hypothesis behind this study is that PLS patients' PMNs produce more proinflammatory cytokines to compensate for their reduced capacity to neutralize leukotoxin and to eliminate Aggregatibacter actinomycetemcomitans. Production of more interleukin (IL)-8 would result in the attraction of more PMNs. Thus, the aim of this study was to evaluate the cytokine profile in PLS patients' blood cultures.

Detailed description

MATERIAL AND METHODS Materials Lipopolysaccharide (LPS; Escherichia coli, serotype R515) was purchased from Alexis (Lausen, Switzerland) and adenosine triphosphate (ATP) from Sigma (Deisenhofen, Germany). Tumor necrosis factor α (TNF-α) was kindly provided by the Knoll AG (Ludwigshafen, Germany). IL-1β was from Invitrogen/Biosource (Karlsruhe, Germany). Patients and healthy donors Five patients with established diagnose of PLS are under periodontal treatment at the Department of Periodontology, Center for Dental, Oral, and Maxillofacial Medicine (Carolinum) of the Johann Wolfgang Goethe-University Frankfurt am Main. Antiinfective therapy with adjunctive antibiotics has been rendered to all of them and they are under regular and frequent supportive therapy. The Department of Periodontology has contact to additional 5 PLS patients that are edentulous or under periodontal therapy elsewhere. All patients underwent complete oral examinations as well as inspection of the skin of the palms and soles. Each adult patient or parents received clinical and genetic counselling, and signed a consent form, approved by the ethic committees of the Universities of Dresden and Frankfurt/Main. Clinical data and mutations of all patients have been reported before. All these patients were invited to take part in this study. Healthy donors had abstained from taking drugs for two weeks prior to the study. Due to wide spread use of oral contraceptives only male probands were chosen. The study complied with the rules of the Declaration of Helsinki and was approved by the Institutional Review Board for Human Studies of the Medical Faculty of the Johann Wolfgang Goethe-University Frankfurt/Main (Application# 31/05). All participating individuals were informed on risks and benefit as well as the procedures of the study and gave written informed consent. Whole blood culture Heparinized blood was mixed with an equal volume of culture medium (RPMI 1640 supplemented with 25 mM HEPES (2-\[4-(2-hydroxyethyl)piperazin-1-yl\]ethanesulfonic acid), 100 U/ml penicillin, 100 µg/ml streptomycin) and 1 ml aliquots were transferred into loosely sealed round-bottom polypropylene tubes (Greiner, Germany). Whole blood cultures were kept at 37 oC and 5 % CO2 for the indicated time periods. Thereafter, cell-free plasma/RPMI samples were obtained by centrifugation and stored at -70oC until assessment of cytokine concentrations by enzyme linked immunosorbent essay (ELISA). Experiments were started within 60 min of blood withdrawal. Thus, the whole blood cultures consisted of the whole range of white blood cells as well as erythrocytes. Except for determination of IL-1β release, cultures were either kept as unstimulated control or stimulated with LPS (10 or 100 ng/ml), or with the combination of IL-1β plus TNF-α (50 ng/ml each) for 24h. For determination of IL-1β release, cells were kept as unstimulated control or were stimulated with Toll-like receptor 4 ligand LPS (100 ng/ml) for altogether 5h. For efficient release of IL-1β from activated cultures, LPS was combined with ATP (2 mM) which was added during the last 2h of the 5h stimulation period in order to achieve activation of the purinoreceptor P2X7. Analysis of cytokine release by ELISA analysis Concentrations of IL-8, IL-6, interferon-inducible protein (IP)-10, interferon (IFN) gamma (Pharmingen/BD Biosciences), and IL-1β, (R&D Systems), in plasma/RPMI samples were determined by ELISA according to the manufacturers' instructions. Statistics The individual patient or proband was defined as statistical unit. Data are shown as median with interquartile range and are presented as pg/ml (IL-1β, IL-6, IP-10) or as ng/ml (IL-8). Medians were compared between PLS patients and healthy volunteers using the non parametric Mann Whitney U test. Statistical analysis was performed using a computer program (Systat for Windows version 10.0, Systat Inc., Evanston, IL, USA).

Interventions

None listed

Sponsors

Goethe University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Healthy volunteers
Yes

Inclusion criteria

* Diagnose of PLS

Exclusion criteria

* No written informed consent

Design outcomes

Primary

MeasureTime frameDescription
Serum Concentrations of Interleukin (IL)-1 Beta2006Concentrations of IL-8, IL-6, IP-10, interferon (IFN)-gamma, and IL-1 beta, in plasma/RPMI samples were determined by enzyme linked immunosorbent assay (ELISA) according to the manufacturers' instructions

Countries

Germany

Participant flow

Participants by arm

ArmCount
PLS Patients
8 PLS patients (one female) from 6 families
8
Healthy Controls
9 healthy donors
9
Total17

Baseline characteristics

CharacteristicPLS PatientsHealthy ControlsTotal
Age, Categorical
<=18 years
5 Participants0 Participants5 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
3 Participants9 Participants12 Participants
Region of Enrollment
Germany
8 participants9 participants17 participants
Sex: Female, Male
Female
1 Participants0 Participants1 Participants
Sex: Female, Male
Male
7 Participants9 Participants16 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 80 / 9
serious
Total, serious adverse events
0 / 80 / 9

Outcome results

Primary

Serum Concentrations of Interleukin (IL)-1 Beta

Concentrations of IL-8, IL-6, IP-10, interferon (IFN)-gamma, and IL-1 beta, in plasma/RPMI samples were determined by enzyme linked immunosorbent assay (ELISA) according to the manufacturers' instructions

Time frame: 2006

Population: Samples were stimulated with 100 ng/ml lipopolysaccharide (LPS)

ArmMeasureGroupValue (MEDIAN)
Papillon-Lefèvre Syndrome (PLS) PatientsSerum Concentrations of Interleukin (IL)-1 Betainterleukin-665559 pg/ml
Papillon-Lefèvre Syndrome (PLS) PatientsSerum Concentrations of Interleukin (IL)-1 Betainterferon gamma3704.5 pg/ml
Papillon-Lefèvre Syndrome (PLS) PatientsSerum Concentrations of Interleukin (IL)-1 Betainterferon-inducible protein-1012902.5 pg/ml
Papillon-Lefèvre Syndrome (PLS) PatientsSerum Concentrations of Interleukin (IL)-1 Betainterleukin-850520 pg/ml
Papillon-Lefèvre Syndrome (PLS) PatientsSerum Concentrations of Interleukin (IL)-1 Betainterleukin-1 beta1100.00 pg/ml
Healthy ControlsSerum Concentrations of Interleukin (IL)-1 Betainterleukin-844390 pg/ml
Healthy ControlsSerum Concentrations of Interleukin (IL)-1 Betainterleukin-1 beta896.21 pg/ml
Healthy ControlsSerum Concentrations of Interleukin (IL)-1 Betainterleukin-645734 pg/ml
Healthy ControlsSerum Concentrations of Interleukin (IL)-1 Betainterferon-inducible protein-1011563 pg/ml
Healthy ControlsSerum Concentrations of Interleukin (IL)-1 Betainterferon gamma3317.4 pg/ml

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026